Jaguar Health announced that the Company is developing an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi, the Company’s FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on JAGX:
- Jaguar Health receives Orphan Drug Designation for crofelemer in MVID
- Jaguar Health receives notice of allowance for U.S. patent
- Jaguar Health reaches 75% enrollement in Phase 3 OnTarget trial of crofelemer
- Jaguar Health announces initial close in private placement financing
- Jaguar Health regains compliance with Nasdaq minimum bid price rule
